While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...
InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its Phase 3 trial for vilobelimab in pyoderma gangrenosum/PG would be ...
JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results